DOI: 10.36347/sjams.2016.v04i10.011

Pages: 3597-3600

Postoperative nausea and vomiting (PONV) is the most common complication of surgery and anesthesia. The incidence of PONV is much higher when spinal anesthesia is administered with intrathecal morphine. Palonosetron is a newer generation 5HT3 antagonist used in the management of Chemotherapy induced Nausea & vomiting. We undertook the study to compare the efficacy of Palonosetron, with placebo in preventing PONV, to assess the severity of PONV, to observe side effects if any and to assess the requirements of rescue antiemetic in the post operative period. 100 ASA 1&2 patients were randomly allocated in 2 groups P & C. Group P received Inj. Palonosetron 1.5ml(0.075mg) iv and Group C received Inj. Saline 1.5ml iv15 minutes before Spinal Anaesthesia. Patients were administered Spinal Anaesthesia in the L3-L4 or L4-L5 space.2.5ml of 0.5% Hyperbaric Bupivacaine with Inj. Morphine 200µg (0.2ml) as per protocol. They were monitored using Nausea score & Vomiting.The Nausea score showed significant differences in the group that received palonosetron as compared to the control group which was more in all through the 24 hour observation period. The severe cases of nausea were significantly more in Group C as compared to Group P.A single intravenous dose of 0.075mg Palonosetron significantly reduces PONV & reduces the need for rescue anti-emetics in first 48hrs, compared to placebo, in patients undergoing infraumbilical surgeries under spinal anaesthesia with Bupivacaine & Morphine.